Ending Lending to China Act of 2025

Senate Bill

S. 2362

119th Congress

Ending Lending to China Act of 2025

In Committee

Introduced:Jul 21, 2025

Primary Sponsor

Amy Klobuchar

D - MN

Cosponsors

6

Quick Stats

Policy Area

Health

Summary

This bill aims to prevent drug shortages by requiring drug manufacturers to notify the Food and Drug Administration (FDA) if they anticipate increased demand, export restrictions, or other issues that could lead to a shortage of critical drugs. It expands reporting requirements for drug manufacturers, including more frequent updates on drug production and supply chain information.

Latest Action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Introduced7/21/2025

StatusRead twice and referred to the Committee on Foreign Relations. (text: CR S4506)

ChamberSenate

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

Ending Lending to China Act of 2025

This bill aims to prevent drug shortages by requiring drug manufacturers to notify the Food and Drug Administration (FDA) if they anticipate increased demand, export restrictions, or other issues that could lead to a shortage of critical drugs. It expands repo

Community Breakdown

Pass

0%

Fail

0%

0 predictions

This bill aims to prevent drug shortages by requiring drug manufacturers to notify the Food and Drug Administration (FDA) if they anticipate increased demand, export restrictions, or other issues that could lead to a shortage of critical drugs. It expands reporting requirements for drug manufacturers, including more frequent updates on drug production and supply chain information.

Bill Number: 2362
Introduced: 7/21/2025
Status: Read twice and referred to the Committee on Foreign Relations. (text: CR S4506)
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: Ending Lending to China Act of 2025
Bill Number: 2362
Sponsor: No sponsor
Status: Read twice and referred to the Committee on Foreign Relations. (text: CR S4506)
Introduced: 7/21/2025
Summary: This bill aims to prevent drug shortages by requiring drug manufacturers to notify the Food and Drug Administration (FDA) if they anticipate increased demand, export restrictions, or other issues that could lead to a shortage of critical drugs. It expands reporting requirements for drug manufacturer

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

This bill aims to prevent drug shortages by requiring drug manufacturers to notify the Food and Drug Administration (FDA) if they anticipate increased demand, export restrictions, or other issues that could lead to a shortage of critical drugs. It expands reporting requirements for drug manufacturers, including more frequent updates on drug production and supply chain information.

Last updated: 12/30/2025

Official Summary

Congressional Research Service summary

Drug Shortage Prevention Act of 2023 This bill requires drug manufacturers to notify the Food and Drug Administration (FDA) if there is an increased demand, export restriction, or other circumstance that may result in a shortage of certain critical drugs. Currently, drug manufacturers are required to notify the FDA in the event of a discontinuation or interruption in the supply of prescription drugs that are life-supporting, life-sustaining, or used for a debilitating disease or condition, including those used in medical emergencies, surgeries, or public health emergencies. The bill requires drug manufacturers to also notify the FDA if there is an increased demand, export restriction, or other circumstance that may result in a meaningful shortfall or delay in meeting the demand for such drugs. Manufacturers must notify the FDA as soon as possible but no later than 10 days after the onset of the relevant circumstance. The notice must include the reasons for the increased demand, the expected duration, and any other information the FDA requires. The bill's requirements apply to both prescription and nonprescription drugs. Drug manufacturers must also report twice a year (rather than annually) information on the quantities of drugs produced; manufacturers must also provide the names of the suppliers of corresponding active ingredients.

Key Points

Main provisions of the bill

Requires drug manufacturers to notify the FDA within 10 days if they expect a shortage of critical drugs due to increased demand, export restrictions, or other factors
Mandates that drug manufacturers report production quantities and supply chain details twice a year, up from the current annual requirement
Applies to both prescription and over-the-counter drugs that are life-supporting, life-sustaining, or used to treat debilitating conditions

How This Impacts Americans

Potential effects on citizens and communities

This bill would affect drug manufacturers and the FDA, as well as patients who rely on critical medications. It aims to give the FDA and the public more visibility into the drug supply chain to help prevent shortages and ensure access to important drugs. Patients could benefit from a more stable and resilient drug supply, while manufacturers would face increased reporting requirements.

Policy Areas

Primary Policy Area

Health

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

2362, 119th Congress (2025). "Ending Lending to China Act of 2025". Source: Voter's Right Platform. https://votersright.org/bills/118-s-2362

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Health

HR 3021

Empowering Patient Choice of Medical Care Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

HR 2111

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Referred to the House Committee on Energy and Commerce.

HR 2884

Anti-Racism in Public Health Act of 2025

Referred to the House Committee on Energy and Commerce.

S 1406

SOAR Act of 2025

Read twice and referred to the Committee on Finance.